Amy Gilbert, Ph.D. is a Senior Director in the Drug Discovery organization at Adaptive Biotechnologies. Amy received her B.A. in biology from Middlebury College and completed her Ph.D. in Immunology at the National Institute for Health Research Biomedical Research Centre at King’s College London. There she studied novel therapeutic approaches to activate innate and adaptive immune responses in melanoma. Prior to joining Adaptive, Amy hold 15+ years of experience in the biotechnology field working at Genentech, Amgen and Kite Pharma, A Gilead company. At Adaptive she leads a team focused on the discovery and development of novel therapeutic approaches for the treatment of cancer, autoimmune and infectious disease.